3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
23
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
58
Colonic Neoplasms
24
Rectal Neoplasms
22
Neoplasms
19
Pancreatic Neoplasms
18
Neoplasm Metastasis
17
Esophageal Neoplasms
9
Stomach Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Small Cell Lung Carcinoma
5
Lung Neoplasms
5
Glioma
5
Glioblastoma
5
Brain Neoplasms
5
Neuroblastoma
4
Gliosarcoma
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Renal Cell
4
Melanoma
3
Intestinal Neoplasms
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Sarcoma, Ewing
2
Recurrence
2
Rectal Diseases
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Interventions
Temozolomide
11
Radiotherapy
11
Filgrastim
6
Granulocyte Colony-Stimulating Factor
4
Chemotherapy, Adjuvant
4
etoposide phosphate
3
Topotecan
3
O(6)-benzylguanine
3
Melphalan
3
Etoposide
3
Cyclophosphamide
3
Carboplatin
3
sodium thiosulfate
2
sargramostim
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Methylphenidate
2
Mannitol
2
Ifosfamide
2
Carmustine
2
Busulfan
2
Bone Marrow Transplantation
2
Bevacizumab
2
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
temsirolimus
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
poly ICLC
1
pentetreotide
1
pemigatinib
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Central Nervous System Neoplasms
×
Irinotecan
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled